Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs TransMedics Group Inc (TMDX) Price & Performance

Norwegian Cruise Line Holdings LtdTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Norwegian Cruise Line Holdings Ltd vs TransMedics Group Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.42 (market cap $8.95B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 3.5× TransMedics Group Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

NCLHTMDX
Market Cap
$8.95B$2.54B
Sector
Consumer CyclicalTechnology
52-Week High
$26.94$150.42
52-Week Low
$14.79$61.99
Enterprise Value
$23.92B$2.94B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Norwegian Cruise Line Holdings Ltd

NCLH trades at $19.45, down slightly by 0.05%, with a neutral technical signal and bearish moving averages. The company reported revenue of $9.83B in 2025, with net income of $423.25M and a profit margin of 4.3%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.23 versus $0.15 expected. Analyst consensus is bullish with a $20.82 price target, and cash flow trends improved to a positive net of $19M in 2025.

The outlook for NCLH is cautiously optimistic, supported by earnings momentum and analyst buy ratings, but risks include high debt levels and macroeconomic sensitivity. Investment opportunity lies in continued operational recovery and potential upside to price targets, while volatility from fuel costs and travel demand poses challenges.

TransMedics Group Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.

Read more on NCLH

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX